Based on a Cardiac Safety Research Consortium Think Tank held in October 2017 on “Detection, Assessment, and Risk Mitigation of Cardiac Safety Signals in Oncology Drug Development, this publication discusses emerging cardio-oncology nuances and the latest regulatory thinking on ways to manage risks.
Request a Genetics in Clinical Trials training session
What You'll LearnMost Recent Flipbooks
Driving High Performance - Shortening study start-up and optimizing revenue generation
Placebo Response Reduction
WCG has developed and validated the industry-leading Placebo Response Reduction training program.
Lack of Training Compromises Trial Results, Expert Says
At its very core, a clinical trial is a measurement system; yet, the industry has not focused enough on training for everyone involved, from investigators all the way down to the patient.
Q&A: The Role of Expert Committees and the Regulatory Landscape
Dr. Seltzer, president and founder of ACI Clinical, and chief scientific officer of WCG Clinical, shared his insights on expert committees during a recent conversation with Bill Stedman.
Q&A with Dr. Nathaniel Katz
Dr. Katz, Chief Science Officer and the founder of Analgesic Solutions, shared his insights during a recent conversation with Mark Opler, MD, PhD, Chief Research Officer at WCG’s MedAvante-ProPhase.
Optimizing SUSAR distribution in a connected– but unharmonized–world
Steven Beales and Joe O’Rourke, vice president, business development talk through some of the difficulties Sponsors face when it comes to safety letter distribution, and how to overcome them.
Quality First: Using Data to Inform Site Selection in CNS
WCG MedAvante-ProPhase espouses a rather simple philosophy: minimize variability, generate cleaner data.
Don’t Do It Alone: To De-Risk Your Next Trial, Seek Outside Expertise